Korean pharmaceutical firms urged to brace for diverse R&D investment portfolios

Amid depressed consumer demand and a slumping economy, Korean pharmaceutical firms plan to focus on a wide variety of R&D new drug projects, including first-generic version, bioequivalence-tested drugs and novel dosage forms so as to enhance research-based corporate images and competitive edge in the domestic ethicals market.

But a large proportion of their total R&D spending is destined fo...